Cargando…

Non-Genomic Actions of the Androgen Receptor in Prostate Cancer

Androgen receptor (AR) is a validated drug target for prostate cancer based on its role in proliferation, survival, and metastases of prostate cancer cells. Unfortunately, despite recent improvements to androgen deprivation therapy and the advent of better antiandrogens with a superior affinity for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leung, Jacky K., Sadar, Marianne D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239799/ https://www.ncbi.nlm.nih.gov/pubmed/28144231 http://dx.doi.org/10.3389/fendo.2017.00002

Ejemplares similares

Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
por: Imamura, Yusuke, et al.
Publicado: (2016)

Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
por: Banuelos, Carmen A., et al.
Publicado: (2020)

FUS/TLS Is a Co-Activator of Androgen Receptor in Prostate Cancer Cells
por: Haile, Simon, et al.
Publicado: (2011)

Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
por: Ito, Yusuke, et al.
Publicado: (2018)

Pin1 inhibition improves the efficacy of ralaniten compounds that bind to the N-terminal domain of androgen receptor
por: Leung, Jacky K., et al.
Publicado: (2021)

Non-Genomic Androgen Action Regulates Proliferative/Migratory Signaling in Stromal Cells
por: Di Donato, Marzia, et al.
Publicado: (2015)

Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers
por: Tien, Amy H., et al.
Publicado: (2022)

Androgen Action in the Ovary
por: Franks, Stephen, et al.
Publicado: (2018)

Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
por: Antonarakis, Emmanuel S., et al.
Publicado: (2016)

Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer
por: Myung, Jae-Kyung, et al.
Publicado: (2017)

Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment
por: Dadwal, Ushashi C., et al.
Publicado: (2018)

The Androgen Receptor in Breast Cancer
por: Giovannelli, Pia, et al.
Publicado: (2018)

Editorial: The Androgen Receptor in Breast Cancer
por: Tesei, Anna, et al.
Publicado: (2021)

Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer
por: Qin, Caipeng, et al.
Publicado: (2022)

Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
por: Hirayama, Yukiyoshi, et al.
Publicado: (2020)

Androgen Receptor in Breast Cancer: From Bench to Bedside
por: Chen, Mengyao, et al.
Publicado: (2020)

Androgen receptor in breast cancer: The “5W” questions
por: Ravaioli, Sara, et al.
Publicado: (2022)

Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
por: Shimizu, Yasuomi, et al.
Publicado: (2018)

Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer
por: Harris, Anna E., et al.
Publicado: (2022)

Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway
por: Benitez, D A, et al.
Publicado: (2007)

Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis
por: Chen, Xiangyu, et al.
Publicado: (2023)

Cytoplasmic Travels of the Ecdysteroid Receptor in Target Cells: Pathways for Both Genomic and Non-Genomic Actions
por: Vafopoulou, Xanthe, et al.
Publicado: (2012)

Editorial: Non Genomic Actions of Thyroid Hormones in Cancer
por: Davis, Paul J., et al.
Publicado: (2019)

The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis
por: Zhang, Xianlu, et al.
Publicado: (2023)

Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes
por: Jillson, Lauren K., et al.
Publicado: (2021)

Novel expressed sequences identified in a model of androgen independent prostate cancer
por: Quayle, Steven N, et al.
Publicado: (2007)

Estrogen Receptors Promote Migration, Invasion and Colony Formation of the Androgen-Independent Prostate Cancer Cells PC-3 Through β-Catenin Pathway
por: Lombardi, Ana Paola G., et al.
Publicado: (2020)

Novel Variant of the Androgen Receptor Gene in a Patient With Complete Androgen Insensitivity Syndrome and Polyorchidism
por: Konrade, Ilze, et al.
Publicado: (2019)

Advances in mitochondria-centered mechanism behind the roles of androgens and androgen receptor in the regulation of glucose and lipid metabolism
por: Yin, Lijun, et al.
Publicado: (2023)

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis
por: Chen, Jiuzhou, et al.
Publicado: (2023)

Non-genomic mechanisms of progesterone action in the brain
por: Singh, Meharvan, et al.
Publicado: (2013)

SAT023 The Role Of Cysteine Residues In The Binding Of Inhibitors Of The N-Terminal Domain Of The Androgen Receptor
por: Deneault, Lauren, et al.
Publicado: (2023)

The Divergent Function of Androgen Receptor in Breast Cancer; Analysis of Steroid Mediators and Tumor Intracrinology
por: Bleach, Rachel, et al.
Publicado: (2018)

Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation
por: Liao, Ross S., et al.
Publicado: (2013)

Assessment of oligometastasis status of prostate cancer following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone using PSA percentage decline rate
por: Li, Xuwen, et al.
Publicado: (2023)

Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes
por: Hussein, Mohamed Ali, et al.
Publicado: (2023)

PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells
por: Liu, Wei, et al.
Publicado: (2021)

SAT022 A Mechanism Of Resistance To Novel Inhibitors Of The N-Terminal Domain Of Androgen Receptor
por: Setiawan, Josie, et al.
Publicado: (2023)

The genomic landscape of prostate cancer
por: Baca, Sylvan C., et al.
Publicado: (2012)

OR08-2 Androgen Receptor- Vs Estrogen Receptor-Mediated Actions in the Development of Distinct Clinical Polycystic Ovary Syndrome (PCOS) Phenotypes
por: Aflatounian, Ali, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_esbrsn3oroi81turul13i0egt3